EP2773336A4 - Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate - Google Patents

Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate

Info

Publication number
EP2773336A4
EP2773336A4 EP11875114.8A EP11875114A EP2773336A4 EP 2773336 A4 EP2773336 A4 EP 2773336A4 EP 11875114 A EP11875114 A EP 11875114A EP 2773336 A4 EP2773336 A4 EP 2773336A4
Authority
EP
European Patent Office
Prior art keywords
halofenate
urate
gout
patients
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11875114.8A
Other languages
German (de)
English (en)
Other versions
EP2773336A1 (fr
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of EP2773336A1 publication Critical patent/EP2773336A1/fr
Publication of EP2773336A4 publication Critical patent/EP2773336A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11875114.8A 2011-11-04 2011-11-04 Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate Withdrawn EP2773336A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (fr) 2011-11-04 2011-11-04 Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate

Publications (2)

Publication Number Publication Date
EP2773336A1 EP2773336A1 (fr) 2014-09-10
EP2773336A4 true EP2773336A4 (fr) 2015-06-03

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11875114.8A Withdrawn EP2773336A4 (fr) 2011-11-04 2011-11-04 Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate

Country Status (13)

Country Link
EP (1) EP2773336A4 (fr)
JP (1) JP6202633B2 (fr)
KR (1) KR20140121383A (fr)
CN (2) CN109908124A (fr)
AU (1) AU2011380507B2 (fr)
CA (1) CA2859686C (fr)
CL (1) CL2014001155A1 (fr)
IL (1) IL232386A0 (fr)
MX (1) MX357507B (fr)
NZ (1) NZ624708A (fr)
SG (1) SG11201402032RA (fr)
WO (1) WO2013066349A1 (fr)
ZA (1) ZA201403575B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (fr) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc Méthode de traitement de l'hyperuricémie, faisant appel à l'halofénate ou à l'acide halofénique et à un agent anti-inflammatoire, chez les patients souffrant de goutte
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
US11446317B2 (en) 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2011032175A1 (fr) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Formulations combinées de tranilast et d'allopurinol et procédés associées à celles-ci

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01399008 on 2011_07_20: ClinicalTrials.gov Archive", 20 July 2011 (2011-07-20), XP055185403, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01399008/2011_07_20> [retrieved on 20150423] *
ANONYMOUS: "NCT01416402 on 2011_10_21: ClinicalTrials.gov Archive", 21 October 2011 (2011-10-21), XP055185406, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01416402/2011_10_21> [retrieved on 20150423] *
GOPAL C SAHA ET AL: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes.", ARTHRITIS & RHEUMATISM, vol. 63, no. 10, Suppl. S, October 2011 (2011-10-01), pages S1014, XP055185501 *
HOWARD S SMITH ET AL: "Gout: Current Insights and Future Perspectives", JOURNAL OF PAIN, vol. 12, no. 11, 28 September 2011 (2011-09-28), pages 1113 - 1129, XP028334440, ISSN: 1526-5900, [retrieved on 20110704], DOI: 10.1016/J.JPAIN.2011.06.009 *
See also references of WO2013066349A1 *

Also Published As

Publication number Publication date
ZA201403575B (en) 2015-11-25
CN104066427A (zh) 2014-09-24
EP2773336A1 (fr) 2014-09-10
MX2014005400A (es) 2015-02-12
CA2859686C (fr) 2018-09-11
JP6202633B2 (ja) 2017-09-27
CL2014001155A1 (es) 2015-01-16
JP2014532758A (ja) 2014-12-08
MX357507B (es) 2018-07-12
NZ624708A (en) 2015-11-27
KR20140121383A (ko) 2014-10-15
AU2011380507B2 (en) 2017-06-15
CA2859686A1 (fr) 2013-05-10
IL232386A0 (en) 2014-06-30
SG11201402032RA (en) 2014-09-26
CN109908124A (zh) 2019-06-21
WO2013066349A1 (fr) 2013-05-10
AU2011380507A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
HRP20180780T1 (hr) Liječenje gihta i hiperurikemije
EP2716669A4 (fr) Procédé de modification de surface et corps élastique présentant une surface modifiée
EP2627331A4 (fr) Méthodes de traitement de l&#39;hyperuricemie et de maladies liées
EP2788075A4 (fr) Dispositif et procédé de réduction de l&#39;impédance transthoracique d&#39;un patient
PT3257546T (pt) Método de preparação de cateter urinário pronto a utilizar
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
AP2015008931A0 (en) Benzothiazole compounds and their pharmaceutical use
PT2663864T (pt) Método de avaliação de imunodiversidade e seu uso
ZA201307742B (en) Method for manufacturing and utilizing ferritic-austenitic stainless steel
EP2739352A4 (fr) Procédé et appareil d&#39;électrothérapie multimodal
PT2717692T (pt) Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas
DK2750705T3 (en) Methods for effectively and rapidly desensitizing allergic patients
PL2413718T3 (pl) Zastosowanie kwasu arachidonowego do zmniejszenia ryzyka insulinooporności w późniejszym życiu
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
SG11201401272RA (en) Method for manufacturing acrylic acid-based polymer and use for same
IL232385A (en) Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder
HK1204913A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent
EP2640376A4 (fr) Dérivés d&#39;acide caféique et leur utilisation dans l&#39;amélioration de la viabilité des cellules neuronales
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
EP2720703A4 (fr) Procédés d&#39;accroissement de la sensibilité à l&#39;insuline et méthodes de traitement du diabète
EP2773261A4 (fr) Manomètre s&#39;utilisant pour tester la région rachidienne et procédé correspondant
GB201003894D0 (en) Inhibitors of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome
EP2548935A4 (fr) Agent de désulfuration et son procédé de fabrication
GB201008519D0 (en) Method and apparatus for restricting ectoparasite infection in fish within a fish pen
EP2768536A4 (fr) Méthode de traitement des diabètes de type i et de type ii

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101AFI20150428BHEP

Ipc: A61K 31/426 20060101ALI20150428BHEP

Ipc: A61P 19/06 20060101ALI20150428BHEP

Ipc: A61K 31/519 20060101ALI20150428BHEP

Ipc: A61K 31/216 20060101ALI20150428BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYMABAY THERAPEUTICS, INC.

Owner name: DIATEX, INC.

17Q First examination report despatched

Effective date: 20180115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190603